Malignant mesothelioma is a rare and aggressive cancer that starts in the thin tissue lining the lungs, abdomen, or other organs, most often linked to asbestos exposure. While this cancer is challenging to treat, a combination of standard therapies and promising new approaches being tested in clinical trials offer hope for managing symptoms, slowing disease progression, and improving quality of life for those affected.

Understanding Your Treatment Path After a Mesothelioma Diagnosis

When someone receives a mesothelioma diagnosis, the main goals of treatment are to control symptoms, slow down how fast the cancer grows, and help patients live as comfortably and as long as possible. Because mesothelioma often develops many years after asbestos exposure and is frequently diagnosed at advanced stages, treatment plans need to be carefully tailored to each person’s situation^[1].

The treatment approach depends on several important factors. Where the cancer is located in the body matters greatly—whether it affects the lining around the lungs, the abdomen, or more rarely, the heart or testicles. The stage of the disease, which describes how far the cancer has spread, plays a crucial role in determining which treatments are possible. The type of mesothelioma cells under the microscope—whether they are epithelioid, sarcomatoid, or a mix of both—also influences treatment choices and expected outcomes. Additionally, a person’s overall health, age, and personal preferences are essential considerations when creating a treatment plan^[2][5].

Medical societies have established standard treatments that have been approved and used for years. At the same time, researchers continue to explore new therapies through clinical trials. These trials test innovative approaches that may offer better results than current standard treatments. Some patients may be eligible to participate in these studies, which can provide access to cutting-edge therapies while contributing to medical knowledge that helps future patients^[3][5].

Standard Treatment Approaches for Mesothelioma

Standard treatment for mesothelioma typically involves a combination of different approaches. This is called multimodal therapy, which means using two or more types of treatment together to attack the cancer from different angles. The main standard treatments include surgery, chemotherapy, radiation therapy, and more recently, immunotherapy^[5][11].

Surgery

Surgery can be an option for patients with early-stage mesothelioma who are healthy enough to undergo a major operation. The type of surgery depends on where the cancer is located and how far it has spread. For pleural mesothelioma affecting the lung lining, surgeons may perform a pleurectomy and decortication, which removes the diseased pleura (the lining around the lung) while keeping the lung intact. In more extensive cases, doctors may consider an extrapleural pneumonectomy, a more aggressive procedure that removes an entire lung along with the surrounding pleura, part of the diaphragm, and the lining around the heart^[11][13].

Not all patients are candidates for surgery. The cancer must be confined enough to be removable, and the patient needs to be strong enough to recover from these demanding operations. Surgery alone rarely cures mesothelioma, which is why it is almost always combined with other treatments like chemotherapy or radiation therapy. Some operations are performed not to remove all the cancer but to relieve symptoms—this is called debulking surgery, where surgeons remove as much tumor as possible to ease breathing difficulties or reduce pain^[11][17].

Chemotherapy

Chemotherapy uses powerful drugs to kill cancer cells throughout the body. For mesothelioma, the most common chemotherapy combination is pemetrexed together with cisplatin. This combination has been the standard first-line chemotherapy for about two decades. Pemetrexed works by interfering with how cancer cells build new DNA, while cisplatin damages the DNA structure itself. Together, they can help shrink tumors and control the cancer’s growth^[16][17].

Patients typically receive chemotherapy through a vein (intravenously) in cycles, with each cycle lasting about 21 days. Treatment usually continues for several cycles as long as it is working and the patient can tolerate it. Clinical studies showed that patients receiving pemetrexed plus cisplatin had a median survival of about 12 months, compared to around 9 months for those receiving cisplatin alone^[16].

For peritoneal mesothelioma, which affects the abdominal lining, doctors sometimes use a special technique called HIPEC (heated intraperitoneal chemotherapy). After surgically removing visible tumors, heated chemotherapy drugs are circulated directly in the abdominal cavity. The heat helps the drugs penetrate more deeply into any remaining cancer cells. This approach has shown promising results for carefully selected patients with peritoneal mesothelioma^[13].

Chemotherapy affects rapidly dividing cells, which unfortunately includes some healthy cells in the body. This leads to side effects that can include nausea, vomiting, fatigue, hair loss, increased risk of infection due to lowered white blood cell counts, and changes in blood cell levels. Kidney damage can occur with cisplatin, so doctors monitor kidney function closely. Most side effects are temporary and improve after treatment ends, and medicines are available to help manage many of these effects^[16][17].

Radiation Therapy

Radiation therapy uses high-energy beams, similar to x-rays, to destroy cancer cells. For mesothelioma, radiation can serve different purposes. It may be used after surgery to kill any remaining cancer cells in the treated area, a technique called adjuvant radiotherapy. Radiation can also be used to control symptoms in patients with advanced disease, such as reducing pain, relieving breathing difficulties, or shrinking tumors that are pressing on nearby structures^[3][11].

The challenge with radiation for mesothelioma is that the cancer often spreads across large areas of the chest or abdomen, making it difficult to target all cancer cells without damaging healthy organs nearby. Newer radiation techniques allow doctors to focus the beams more precisely on tumor tissue while minimizing exposure to surrounding healthy tissue. Side effects of radiation can include skin irritation in the treated area, fatigue, and temporary inflammation of nearby organs^[11][17].

Immunotherapy

Immunotherapy is a newer standard treatment that has changed the landscape of mesothelioma care in recent years. Unlike chemotherapy, which directly kills cancer cells, immunotherapy works by helping the body’s own immune system recognize and attack cancer cells. Cancer cells often have ways of hiding from the immune system, and immunotherapy drugs can remove these disguises^[3][16].

In 2020, the combination of nivolumab plus ipilimumab was approved as a first-line treatment for patients with unresectable (cannot be removed by surgery) malignant pleural mesothelioma. Nivolumab and ipilimumab are checkpoint inhibitors—they block proteins that prevent immune cells from attacking cancer. In a major clinical trial called CheckMate-743, patients receiving nivolumab plus ipilimumab lived longer than those receiving standard chemotherapy. The median overall survival was about 18 months with immunotherapy compared to 14 months with chemotherapy. Importantly, patients with non-epithelioid types of mesothelioma—which are usually harder to treat—seemed to benefit especially from this immunotherapy combination^[16][17].

Another checkpoint inhibitor, pembrolizumab, can also be used for metastatic mesothelioma that cannot be removed by surgery. These immunotherapy drugs are given through an intravenous infusion every few weeks. Side effects are different from chemotherapy and occur because the immune system becomes more active. They can include fatigue, skin rashes, diarrhea, and inflammation of various organs. Most side effects are manageable, but doctors monitor patients closely because serious immune-related side effects can sometimes occur^[16][17].

Duration and Coordination of Standard Therapies

The duration of treatment varies greatly depending on the approach. Chemotherapy typically continues for four to six cycles if it is working and tolerated well. Immunotherapy may continue for up to two years or until the cancer progresses or side effects become too severe. Radiation therapy courses usually last several weeks with daily treatments. For patients receiving multimodal therapy—such as surgery followed by chemotherapy and radiation—the entire treatment process can extend over many months^[14][17].

Clinical guidelines recommend that mesothelioma patients be evaluated by a team of specialists including medical oncologists (who manage chemotherapy and immunotherapy), surgical oncologists (who perform operations), radiation oncologists (who deliver radiation treatment), and other support staff. This team approach ensures that all treatment options are considered and coordinated effectively^[11][18].

Promising Treatments Being Tested in Clinical Trials

Clinical trials are research studies that test new treatments before they become widely available. For mesothelioma, which remains a challenging cancer to treat with standard therapies alone, clinical trials offer hope for better outcomes. These studies are carefully designed to determine whether new approaches are safe and effective^[3][5].

Understanding Clinical Trial Phases

Clinical trials happen in phases, each with a specific purpose. Phase I trials focus primarily on safety—researchers want to know what side effects occur, what doses can be given safely, and how the body processes the new treatment. These studies usually involve small numbers of patients. Phase II trials test whether the treatment actually works against the cancer—does it shrink tumors or help patients live longer? These trials involve more patients. Phase III trials compare the new treatment directly to the current standard treatment to see which works better. These are large studies that can involve hundreds or even thousands of patients. If Phase III results are positive, the treatment may be approved for general use^[3][5].

New Immunotherapy Combinations

Building on the success of nivolumab plus ipilimumab, researchers are testing additional immunotherapy approaches. Some trials are combining checkpoint inhibitors with chemotherapy to see if adding immune activation to standard chemotherapy produces even better results. Early studies of chemoimmunotherapy—chemotherapy combined with immunotherapy drugs—have shown promise in mesothelioma. The idea is that chemotherapy might make cancer cells more visible to the immune system, while immunotherapy arms the immune system to attack more effectively^[15].

Researchers are also investigating whether combining different types of immunotherapy drugs together might work better than using them alone. These combinations may include checkpoint inhibitors that block different immune pathways, potentially giving the immune system multiple ways to recognize and destroy cancer cells^[15].

Targeted Therapy Approaches

Targeted therapy involves drugs designed to attack specific molecules or pathways that cancer cells use to grow and survive. Unlike chemotherapy, which affects many types of rapidly dividing cells, targeted therapies are meant to be more selective. Several targeted approaches are being studied in mesothelioma clinical trials^[15][17].

One area of focus involves drugs that block signals telling cancer cells to grow and divide. These might include inhibitors of growth factor receptors or proteins involved in cancer cell survival. Another approach targets the blood vessels that feed tumors. Cancer cells need nutrients and oxygen delivered by blood vessels to grow, and drugs that prevent new blood vessel formation—called angiogenesis inhibitors—can potentially starve tumors. Some of these targeted drugs are pills taken by mouth, while others are given intravenously^[15][17].

Researchers have also been studying the genetics of mesothelioma cells to identify specific mutations or changes that might be targets for treatment. Some patients with mesothelioma have alterations in a gene called BAP1, which normally helps prevent cancer. Understanding these genetic changes may lead to therapies specifically designed for patients whose tumors have particular genetic characteristics^[4][15].

Cellular Therapies

Cellular therapy represents one of the most innovative approaches being explored in mesothelioma research. One type involves engineering a patient’s own immune cells to better recognize and attack cancer. CAR-T cell therapy (chimeric antigen receptor T-cell therapy) involves collecting immune cells called T cells from a patient’s blood, modifying them in a laboratory to express special receptors that recognize mesothelioma cells, then infusing the engineered cells back into the patient. These modified T cells can then seek out and destroy cancer cells throughout the body^[15].

Another cellular approach being studied involves vaccines. Unlike vaccines that prevent disease, cancer vaccines are designed to treat existing cancer by training the immune system to recognize cancer cells as foreign invaders. Some experimental mesothelioma vaccines are applied locally during surgery, while others are injected under the skin or into the bloodstream. These vaccines aim to create a long-lasting immune response against the cancer^[15].

Gene Therapy and Viral Therapies

Gene therapy approaches aim to introduce genetic material into cancer cells or surrounding cells to fight the tumor. Some experimental treatments use modified viruses that can infect and kill cancer cells preferentially while leaving healthy cells alone. These oncolytic viruses are engineered to replicate inside cancer cells, causing them to burst and die while also triggering an immune response against the tumor. Early-phase trials are exploring different viral vectors and delivery methods for mesothelioma^[15].

Trial Results and Eligibility

Some clinical trials have reported encouraging preliminary results. For instance, certain immunotherapy combinations in Phase II trials have shown that a portion of patients experience tumor shrinkage or disease stabilization lasting many months. Some chemoimmunotherapy studies have reported overall survival extending beyond what is typically seen with chemotherapy alone. Early cellular therapy studies have demonstrated that it is feasible to generate and administer engineered immune cells to mesothelioma patients, with some patients showing positive responses^[15][16].

Clinical trials for mesothelioma are conducted at specialized cancer centers across the United States, Europe, and other regions. Some trials may be available in only a few locations, while others are open at multiple sites. Eligibility for trials depends on many factors including the type and stage of mesothelioma, previous treatments received, overall health status, and specific characteristics of the tumor. Age, kidney and liver function, and other medical conditions may also affect eligibility. Patients interested in clinical trials should discuss options with their treatment team early in the decision-making process^[3][5].

Most Common Treatment Methods

• Surgery
  • Pleurectomy and decortication: Removes the diseased lining around the lung while preserving the lung itself
  • Extrapleural pneumonectomy: Removes the entire affected lung along with surrounding tissue in extensive cases
  • Debulking surgery: Removes as much tumor as possible to relieve symptoms when complete removal is not possible
  • Cytoreductive surgery with HIPEC: For peritoneal mesothelioma, removes visible tumors followed by heated chemotherapy directly in the abdomen
• Chemotherapy
  • Pemetrexed plus cisplatin: The standard first-line chemotherapy combination for pleural mesothelioma given intravenously every 21 days
  • Carboplatin may be used instead of cisplatin for patients who cannot tolerate cisplatin
  • HIPEC (heated intraperitoneal chemotherapy): Heated chemotherapy drugs circulated directly in the abdominal cavity after surgery for peritoneal mesothelioma
• Immunotherapy
  • Nivolumab plus ipilimumab: Checkpoint inhibitor combination approved for first-line treatment of unresectable pleural mesothelioma
  • Pembrolizumab: Another checkpoint inhibitor used for metastatic mesothelioma
  • These drugs work by helping the immune system recognize and attack cancer cells
• Radiation Therapy
  • Adjuvant radiation: Used after surgery to eliminate remaining cancer cells in the treated area
  • Palliative radiation: Controls symptoms such as pain or breathing difficulties in advanced disease
  • Focused beam techniques help target tumors while protecting healthy tissue
• Multimodal Therapy
  • Combines two or more treatment types such as surgery followed by chemotherapy and radiation
  • Trimodality therapy involves surgery, chemotherapy, and radiation used together in sequence
  • Chemoimmunotherapy combines chemotherapy with immunotherapy drugs
• Targeted Therapy (Clinical Trials)
  • Drugs that block specific growth signals in cancer cells
  • Angiogenesis inhibitors that prevent tumors from forming new blood vessels
  • Treatments designed for specific genetic changes in mesothelioma cells such as BAP1 mutations
• Cellular Therapy (Clinical Trials)
  • CAR-T cell therapy: Patient’s immune cells are modified to recognize and attack mesothelioma cells
  • Cancer vaccines: Designed to stimulate immune response against tumor cells
  • Oncolytic viral therapy: Uses modified viruses to infect and destroy cancer cells
• Palliative Care
  • Procedures to drain fluid buildup in the chest or abdomen to relieve breathing difficulties
  • Pain management with medications and other techniques
  • Nutritional support to maintain strength during treatment
  • Breathing support and oxygen therapy when needed